title: Purinergic component in the coronary vasodilatation to acetylcholine after ischemia-reperfusion in perfused rat hearts.
abstract: To determine the involvement of purinergic receptors in coronary endothelium-dependent relaxation, the response to acetylcholine (1 × 10(-8) to 3 × 10(-7)M) was recorded in isolated rat hearts perfused according to the Langendorff procedure before and after 30 min of ischemia and 15 min of reperfusion and after the inhibition of nitric oxide synthesis with L-NAME (10(-4)M), in the absence and presence of the antagonist of purinergic P2X receptors, PPADS (3 × 10(-6)M), and of the antagonist of purinergic P2Y receptors, Reactive Blue 2 (3 × 10(-7)M). In control conditions, the relaxation to acetylcholine was not altered by PPADS or Reactive Blue 2. The relaxation to acetylcholine was reduced after ischemia-reperfusion, and, in this condition, it was further reduced by treatment with PPADS or Reactive Blue 2. Likewise, the relaxation to acetylcholine was reduced by L-NAME, and reduced further by Reactive Blue 2 but not by PPADS. These results suggest that the relaxation to acetylcholine may be partly mediated by purinergic receptors after ischemia-reperfusion, due to the reduction of nitric oxide release in this condition.
authors.affiliation: Departamento de Fisiología, Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, Spain.
authors.forename: Ángel Luis
authors.initials: ÁL
authors.lastname: García-Villalón
authors.forename: Miriam
authors.initials: M
authors.lastname: Granado
authors.forename: Luis
authors.initials: L
authors.lastname: Monge
authors.forename: Nuria
authors.initials: N
authors.lastname: Fernández
authors.forename: Gonzalo
authors.initials: G
authors.lastname: Carreño-Tarragona
authors.forename: Sara
authors.initials: S
authors.lastname: Amor
mesh_terms: D000109:Acetylcholine / Q000494:pharmacology*; D000818:Animals; D003326:Coronary Circulation / Q000187:drug effects* / Q000502:physiology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006321:Heart / Q000187:drug effects / Q000502:physiology*; D008297:Male; D015428:Myocardial Reperfusion Injury / Q000188:drug therapy* / Q000503:physiopathology; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology; D009599:Nitroprusside / Q000494:pharmacology; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D058920:Purinergic P2X Receptor Antagonists / Q000494:pharmacology; D058921:Purinergic P2Y Receptor Antagonists / Q000494:pharmacology; D011732:Pyridoxal Phosphate / Q000031:analogs & derivatives / Q000494:pharmacology; D017207:Rats, Sprague-Dawley; D058469:Receptors, Purinergic P2X / Q000502:physiology*; D058470:Receptors, Purinergic P2Y / Q000502:physiology*; D014227:Triazines / Q000494:pharmacology; D014664:Vasodilation / Q000187:drug effects / Q000502:physiology; D014665:Vasodilator Agents / Q000494:pharmacology
chemical_list: D004791:Enzyme Inhibitors; D010975:Platelet Aggregation Inhibitors; D058920:Purinergic P2X Receptor Antagonists; D058921:Purinergic P2Y Receptor Antagonists; D058469:Receptors, Purinergic P2X; D058470:Receptors, Purinergic P2Y; D014227:Triazines; D014665:Vasodilator Agents; C077792:pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid; D009599:Nitroprusside; C012842:Cibacron Blue F 3GA; D011732:Pyridoxal Phosphate; D000109:Acetylcholine; D019331:NG-Nitroarginine Methyl Ester